Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ingenol mebutate vs 5% 5-fluorouracil vs 5% Imiquimod vs photodynamic therapy for actinic keratosis
2014-003691-23Phase 4Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2014
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ingenol mebutate, fluorouracil, imiquimod and methyl aminolevulinate in actinic keratosis (AK) (4 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Treatment success at 12 months. Started Sep 2014; status: completed.
02
Drugs
ingenol mebutatefluorouracilimiquimodmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2014-003691-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003691-23.